39 results about "Metoprolol Tartrate" patented technology

The invention discloses a metoprolol tartrate extended release compound which comprises a. a hollow pill core; b. an active medicine layer containing metoprolol or medicine salt of the metoprolol and at least a bond, and the layer is positioned on the surface of the hollow pill core; c. a release coat layer containing acrylic acid resin NE30D and French chalks, and the release coat layer is positioned outside the active medicine layer. The invention also discloses a method of preparing the medicine compound.

A tartaric acid metoprolol slow release capsules and its preparation. It is prepared by tartaric acid metoprolol, slow release materials and findings in the weight ratio of 25-100:5-20:131-165 to preparing slow-release pellets with different release degree, the slow release materials are one to four of acrylic resin, hydroxypropyl methyl cellulose, ethyl cellulose, phthalate vinegar acid cellulose and polyvinylpyrrolidone; the content of tartaric acid metoprolol in single capsules is 25-100mg. Preparation method uses rolling shaping pill mean. The capsule can maintain balanced and durable effective blood drug concentration in the same dosage and time intervals, or decreases dosage and side effects remaining same drug effect; In particular, it is dispersable agent, it not only can improve the contact area of gastrointestinal tract to making drug absorption completely and the bioavailability higher, and it can get ideal release drugs rate using different pellets combination. In addition, the craft of preparation method used is simple and easy to operating and controlling.

The invention provides metoprolol slow-release microsphere, slow-release medical composition and a preparation method of the metoprolol slow-release microsphere. The metoprolol slow-release microsphere comprises 8-40wt% of active pharmaceutical ingredients and 60-92wt% of slow-release materials, wherein the active pharmaceutical ingredients contain metoprolol succinate, metoprolol tartrate or metoprolol hydrochloride, and the slow-release materials include 65-75wt% of ethyl cellulose and 25-35wt% of poly amino methacrylate. The active pharmaceutical ingredients and the slow-release materials are dissolved in an organic solvent to prepare microsphere, then the microsphere and an excipient are mixed to be pressed into tablets or manufactured into capsules to achieve the slow-release medicalcomposition containing the metoprolol slow-release microsphere. The medical composition is simple in prescription, low in toxicity, high in package rate, strong in controllability, good in reproducibility and low in cost.

The invention provides a novel metoprolol tartrate-containing matrix sustained-release tablet, i.e. a metoprolol tartrate matrix sustained-release tablet with a regulation layer. The novel double-layer matrix sustained-release tablet with the regulation layer is prepared by adding the regulation layer on the basis of the traditional metoprolol tartrate matrix sustained-release tablet, can release medicines uniformly in 24 hours, overcomes the defects of the metoprolol tartrate sustained-release tablet in the prior art, and has the advantages of ideal release effect, simple process and low cost.

The invention discloses a metoprolol tartrate sustained-release tablet and a preparation method thereof. The metoprolol tartrate sustained-release tablet is prepared from the following components in percentage by weight: 39-57 percent of metoprolol tartrate, 17-31 percent of retardant, 4-15 percent of adhesive, 9-24 percent of filler, 1-3 percent of lubricant, 1-2 percent of flow aid and 1-4 percent of coating premix. According to the preparation method, a method of twice separately granulating metoprolol tartrate and partial medicinal auxiliaries is adopted, and a fluidized bed is adopted for granulating. Compared with a traditional wet granulation method, the preparation method has the advantages that raw and auxiliary materials are separately granulated by the fluidized bed according to different properties, and play roles in improving particle fluidity, in particular resisting viscosity. The preparation is good in stability, good in releasing rate, and is beneficial to clinical use. The method is easy to operate, is suitable for large-scale industrial production, and has a higher application value.

The invention provides a Metoprolol Tartaric Acid and Felodipine slow-release double-layer tablet and its preparation method. The slow-release double-layer tablet comprises a Metoprolol Tartaric Acid slow-release layer containing, by weight, 50 parts of Metoprolol Tartaric Acid, 100-150 parts of an ethyl cellulose powder, 24-30 parts of ethyl cellulose in the form of an ethyl cellulose aqueous suspension and 130-230 parts of hydroxypropyl methyl cellulose; and a Felodipine slow-release layer containing 5 parts of Felodipine and 60 parts of hydroxypropyl methyl cellulose. By adjusting the ingredients and their ratio in the Metoprolol Tartaric Acid slow-release layer and the Felodipine slow-release layer, the release speeds of medicament layers can cooperate with each other and the slow-release effect is more reliable, thus reaching a good curative effect; in addition, it is ensured that the medicament layers can be smoothly compacted to form a double-layer tablet, and the hidden trouble of damaged coating particles can be avoided. The preparation method provided by the invention mainly employs the double-layer tablet compacting technology with simple equipment, can save cost and is suitable for industrial production.

The invention discloses water soluble medicament sustained-release tablets, which comprise the following components in part by weight: water soluble medicament 1-30, octadecanol 5-70, Eudragite L 100-55 2-50, talcpowder 2-30 and lactose 2-30. The water soluble medicament may be galanthamine hydrobromide, captopril, metoprolol tartaric acid or pseudoephedrine hydrochloride. In the invention, the octadecanol serving as a hydrophobic auxiliary material and the Eudragite L 100-55 sreving as a water soluble polymer auxiliary are adopted, so the release speed of the medicament can be controlled properly. The Eudragite L 100-55 is insoluble in gastric juice, but dissolves in duodenal juice to make high-viscosity sticky liquid, and thus the release and diffusion speed of the medicament can be reduced. The talcpowder which is a hydrophilic matter insoluble in water plays a porogen role in the sustained-release tablets. In the invention, the release speed of the medicament is regulated by regulating the mixing ratio of the medicament to the auxiliary material. Thus, the release speed of an active medicament is controlled.

The invention relates to a slow-release medicinal preparation for treating heart diseases, especially to a metoprolol slow-release medicinal preparation with mesoporous silica as a carrier, belonging to the field of pharmacy. The slow-release medicinal preparation for treating heart diseases is composed of metoprolol and mesoporous silica nanoparticles. The invention has the following advantages: the preparation method is simple, and the bore diameter of the carrier is controllable; Compared with common preparations, the metoprolol tartrate low-release preparation provided by the invention has the advantages of slower, more sustainable and more stable in-vitro release; the metoprolol tartrate low-release preparation can guarantee control of attack by high blood pressure and myocardial ischemia around the clock; so the metoprolol tartrate low-release preparation has good clinical application prospects.

The invention discloses an MBA bridged cyclodextrin functionalized chiral monolithic column and preparation and application thereof, and belongs to the field of analytical chemistry. According to theMBA bridged cyclodextrin functionalized chiral monolithic column, a cyclodextrin SH-beta-CD and a ligand derivatizing agent MBA are first dissolved in deionized water, a bridged cyclodextrin is formedby a reaction under the condition of AIBA as an initiator, then a nucleophilic reagent urea and a protonation reagent formaldehyde solution are added, and the MBA bridged cyclodextrin functionalizedchiral monolithic column is prepared by one-step polymerization under the action of the catalyst urea. A method for preparing the MBA bridged cyclodextrin functionalized chiral monolithic column is simple, the reaction is fast, a cyclodextrin bimolecular bridged structure constructed through a functional bridge can fully exert the synergistic effect between every two molecules and a bridge chain,the chiral recognition ability of a stationary phase is significantly enhanced, the MBA bridged cyclodextrin functionalized chiral monolithic column is enabled to show excellent resolution ability todifferent types of chiral drugs such as amino acid and metoprolol tartrate in electrochromatography, and thus the MBA bridged cyclodextrin functionalized chiral monolithic column can be used in the field of chiral resolution of the drugs.

The invention provides a Metoprolol Tartaric Acid and Felodipine slow-release double-layer tablet and its preparation method. The slow-release double-layer tablet comprises a Metoprolol Tartaric Acid slow-release layer containing, by weight, 50 parts of Metoprolol Tartaric Acid, 100-150 parts of an ethyl cellulose powder, 24-30 parts of ethyl cellulose in the form of an ethyl cellulose aqueous suspension and 130-230 parts of hydroxypropyl methyl cellulose; and a Felodipine slow-release layer containing 5 parts of Felodipine and 60 parts of hydroxypropyl methyl cellulose. By adjusting the ingredients and their ratio in the Metoprolol Tartaric Acid slow-release layer and the Felodipine slow-release layer, the release speeds of medicament layers can cooperate with each other and the slow-release effect is more reliable, thus reaching a good curative effect; in addition, it is ensured that the medicament layers can be smoothly compacted to form a double-layer tablet, and the hidden trouble of damaged coating particles can be avoided. The preparation method provided by the invention mainly employs the double-layer tablet compacting technology with simple equipment, can save cost and issuitable for industrial production.

The invention provides a metoprolol tartrate sustained release tablet. The metoprolol tartrate sustained release tablet is prepared from the following components in percentage by mass: 100 of metoprolol tartrate, 60-80 of retardant, 20-40 of filling agent, 2-10 of lubricating agent, 50-90 of adhesive and 2.5-4 of film coating powder. Aiming at the problem that adhesive brewing is easily caused in production because the metoprolol tartrate is easy to dissolve in water, the invention provides a two-step granulation method comprising the steps of respectively preparing medicine contained granules and blank granules, drying the medicine contained granules and the blank granules, totally mixing the medicine contained granules and the blank granules and tabletting, so that the problem of adhesive brewing in tabletting is solved. In addition, the metoprolol tartrate is strong in moisture absorption property and bitter in taste, and a coating layer can be used for improving the stability of the metoprolol tartrate and masking the bitter taste of the metoprolol tartrate. The metoprolol tartrate sustained release tablet has the advantages that the components of the auxiliary materials are simple, the operation is convenient, the prepared granules are good in flowability, strong in adhesive resistance and incapable of causing adhesive brewing during tabletting, and the coating layer can be used for improving the stability of a drug and masking the bitter tastes of active ingredients and has no affect to the release rate of the tablet. The metoprolol tartrate sustained release tablet is suitable for industrial production and relatively high in application value.

The invention relates to a method for preparing metoprolol tartrate particles by a using a high-efficiency wet method mixing granulator. According to the method, a specific variety of auxiliary materials in a certain ratio are involved, and the metoprolol tartrate particles are prepared by using a coating material acrylic resin No.2 white oil ethanol solution as adhesive; the method is obviously superior to the conventional method in which starch and dextrin slurry are used; and the metoprolol tartrate particles prepared by the method are simple in preparation process, high in flowability andcompressibility, and strong in bond resistance, have the effect of insulating air to be prevented from being moisturized and oxidized, and are particularly suitable for being stuffed into capsules and pressed into tablets; and the quality problems that the metoprolol tartrate is easy to dissolve and stick and the like can be effectively solved.

The invention belongs to the field of medicinal preparation and discloses a metoprolol tartrate sustained release pellet and a preparation method thereof. The pellet is prepared by the following steps: preparing a parent kernel and a pellet core by using a centrifugal granulation method and spraying a sustained release coat on the pellet by using a fluidized bed coating method; and the method specifically comprises the following steps: (a) preparation of the parent kernel: taking metoprolol tartrate fine powder; adding the metoprolol tartrate fine powder into a pellet processing machine; spraying a wetting agent into the fine powder so as to form a certain number of parent kernels; and screening the parent kernels by using a screening method; (b) preparation of the pellet core: taking the parent kernels; adding the parent kernels into the pellet processing machine; spraying a wetting agent so that the surfaces of the parent kernels are wet; meanwhile, feeding the metoprolol tartrate fine powder into the pellet processing machine so that the parent kernels are laminated to be grown to pellet cores; and screening the pellet cores by using a screening method so as to obtain target pellet cores; and (c) coating of the pellet cores: taking the pellet cores; adding the pellet cores into a fluidized bed; and spraying sustained release coats on the pellet cores by using the fluidized bed coating method. The metoprolol tartrate sustained release pellet disclosed by the invention has the advantages of high true sphericity, small particle size, uniform particle size distribution, low production cost and medicine content of 100% in the pellet core.

The invention belongs to the technical field of a medicine, and in particular relates to a pharmaceutical composition containing metoprolol tartrate and a preparation method of the pharmaceutical composition. The pharmaceutical composition consists of the following components: 40-50% of metoprolol tartrate, 30-40% of microcrystalline cellulose, 5-13% of hydroxypropyl methylcellulose, 2-5% of a povidone K30 ethanol solution, 2-4% of silicon dioxide and 2-4% of magnesium stearate. Through a conventional matrix embedding technology, the medicines are directly dispersed in a skeleton formed by a polymer material, so that a release rate is reduced. As the preparation is taken, the fluctuation amplitude of plasma concentration is relatively low and the peak-valley phenomenon of the plasma concentration is gentle compared with a tablet; and the pharmaceutical composition is low in cost of crude medicines, low in processing cost and high in safety.

The invention belongs to the medical field of medicines, and relates to an extruded 3D printed coating type sustained release preparation and a preparation method thereof. According to the coating type sustained release preparation disclosed by the invention, a mixture of gelatin, glycerin and water is used as a substrate, a medicine or HPMC is added, an inner core or a coating is obtained, then through combination with model slicing and printing parameters, extruding and 3D printing are performed, and a target namely the coating type sustained release preparation is obtained. The formula hasgood printing properties, and takes account of smooth extruding and quick deposition; and compared with a conventional slow release printing material, the extruded 3D printed coating type sustained release preparation has the advantages that the water content of a system is reduced, and intensity and elasticity of samples are improved. An optimized coating model structure can solve the problems existing in a conventional extruded 3D printed sustained release preparation, including low medicine loading quantity, obvious early stage sudden release and not ideal 24h slow release actions. According to the extruded 3D printed coating type sustained release preparation disclosed by the invention, diclofenac sodium, aminophylline, metoprolol tartrate and acetylsalicylic acid are further used as representatives, the application effect of the coating type sustained release preparation is disclosed, and through adjusting medicines and models, individualized treatment of various medicines can berealized.

The invention provides a metoprolol tartrate sustained-release tablet and a preparation method thereof. The tablet is composed of the components of, by weight: 30-50% of metoprolol tartrate, 15-30% of a sustained-release framework material, 0.35-10.0% of a lubricant, 10.0-30.0% of an adhesive, 0.5-5.0% of a film coating premix, and 10.0-30.0% of purified water. Compared with prior art, the tablet and the method provided by the invention have the advantages of simple preparation method, low production cost, suitability for industrialized productions, no greasy and sticky phenomenon during a production process, and smooth release curve. With the tablet, a sudden release phenomenon of a first time period is prevented, and a phenomenon of unqualified release speed at a first time period is also prevented.

The invention discloses a metoprolol tartrate injection and a preparation method thereof. The metoprolol tartrate injection is prepared from the following components: 1g metoprolol tartrate, 9g of sodium chloride, 10 to 15ml of absolute ethanol, 1 to 3g of poloxamer 188 and 1,000ml of water for injection. The metoprolol tartrate injection and the preparation method thereof use the ethanol and the surfactant poloxamer to promote the transfer of the metoprolol between lipid substances in blood and tissues; and the synergistic effect shortens the onset time of the metoprolol tartrate to about 6.4 minutes so as to win more than 3 minutes of precious time for a patient with acute myocardial infarction.

The invention discloses a compound preparation containing benidipine hydrochloride and metoprolol tartrate and an application thereof; for the preparation, the benidipine hydrochloride and the metoprolol tartrate are taken as active pharmaceutical ingredients. The compound pressure-reducing preparation adopts drug combination and is good in efficacy, less in side effects and high in performance-price ratio; the compound preparation is taken once per day, the administration is convenient and the drug compliance of a patient can be improved. The preparation can be prepared into oral formulations in different forms, thereby realizing synergic and complementary action of drugs and enhancing the treatment effect of the compound preparation. The compound preparation has significant effects for treating hypertension and can also be used for treating angina pectoris, myocardial infarction and arrhythmia, as well as hypertrophic cardiomyopathy, aortic dissection, hyperthyroidism, cardiac neurosis, chronic stable heart failure and other symptoms. The compound preparation is low in price, simple to prepare and convenient to popularize and apply.

The invention discloses a metoprolol tartrate extended release compound which comprises a. a hollow pill core; b. an active medicine layer containing metoprolol or medicine salt of the metoprolol and at least a bond, and the layer is positioned on the surface of the hollow pill core; c. a release coat layer containing acrylic acid resin NE30D and French chalks, and the release coat layer is positioned outside the active medicine layer. The invention also discloses a method of preparing the medicine compound.

The invention provides a preparation method of metoprolol sustained release tablets and in particular relates to a preparation method of metoprolol tartrate sustained release tablets. A framework material of a specific model number is adopted and the sustained release tablets are prepared according to a fixed ratio; the obtained sustained release tablets are stable and reliable in quality.

The invention belongs to the field of pharmaceutical medicine, and relates to an extrusion 3D printing coating type sustained-release preparation and a preparation method thereof. The coated sustained-release preparation of the present invention is based on a mixture of gelatin, glycerin and water, adding drugs or HPMC to obtain an inner core or coating, and then extruding 3D printing in combination with model slices and printing parameters to obtain the target coating sustained-release preparations. The formula has good printability, taking into account "smooth extrusion" and "rapid deposition". Compared with the existing slow-release printing materials, the water content of the system is reduced, and the strength and elasticity of the sample are increased. The optimized coating model structure can solve the problems existing in the existing extrusion 3D printing sustained-release preparations, including: low drug loading, obvious early burst release and unsatisfactory 24h sustained-release behavior. The present invention is further represented by diclofenac sodium, aminophylline, metoprolol tartrate and acetylsalicylic acid, disclosing the application effect of coated sustained-release preparations, proving that by adjusting the drugs and models, the individualization of various drugs can be realized treat.

The invention belongs to the technical field of medicines and particularly relates to a metoprolol tartrate crystal, pharmaceutical composition containing the crystal and preparation methods of the metoprolol tartrate crystal and the pharmaceutical composition. The metoprolol tartrate crystal has the chemical structural formula shown in the description. The characteristic peak of an X-ray powder diffraction spectrum obtained through Cu-K alpha ray measurement is shown when 2 theta is 10.65 degrees, 12.98 degrees, 14.28 degrees, 15.03 degrees, 15.89 degrees, 16.93 degrees, 18.13 degrees, 19.45degrees, 20.43 degrees, 20.87 degrees, 21.66 degrees, 22.39 degrees, 23.20 degrees, 23.62 degrees and 24.06 degrees. The pharmaceutical composition containing the crystal is prepared from, in percentage by weight, 21%-45% of the metoprolol tartrate crystal, 36%-53% of starch, 6%-8% of low-substituted hydroxypropyl cellulose, 7%-11% of sodium carboxymethyl starch, 4%-6% of silicon dioxide, 1% of magnesium stearate and a proper amount of hydroxypropyl methylcellulose. Compared with the prior art, the obtained pharmaceutical composition has better solubility and excellent efficacy.

The invention discloses an oil-in-water type metoprolol tartrate / seabuckthorn oil nanoemulsion antihypertensive drug which is characterized in that the nanoemulsion antihypertensive drug has particle size of 30.1-71.8 nm. The drug comprises the following raw materials by weight: 1-20% of metoprolol tartrate, 15-40% of surfactant, 1-25% of co-surfactant, 1-25% of seabuckthorn oil, and the balance of distilled water. The sum of the mass percent of the raw materials is 100%. The nanoemulsion preparation organically combines water-soluble drug metoprolol tartrate and lipid-soluble seabuckthorn oil, to improve dissolution and penetration abilities of seabuckthorn oil, and improve stability and medicinal effect of metoprolol tartrate. The metoprolol tartrate / seabuckthorn oil nanoemulsion combines advantages of metoprolol tartrate and seabuckthorn oil to obviously improve antihypertensive effect, prolong half life of drug, and reduce administration times.

The invention provides an anti-aging composition and a preparation method thereof, and relates to the technical field of anti-aging. The anti-aging composition comprises components: 1-20 parts of nicotinamide dinucleotide, 1-20 parts of hyaluronic acid, 1-20 parts of vitamin B3, 1-20 parts of vitamin B9, 1-20 parts of aspirin enteric-coated tablets, 1-20 parts of vitamin D3, 1-20 parts of metoprolol tartrate tablets, 1-20 parts of resveratrol and 1-20 parts of rhodiola rosea extract. The invention further provides the preparation method of the anti-aging composition. The anti-aging compositionhas the advantages that nicotinamide dinucleotide, hyaluronic acid and the like are added, so that small lesions in a body can be effectively removed, the human body does not have diseases or rarelyhas diseases; meanwhile, by adding the vitamins, the immunity of the body can be effectively improved, the metabolism of the body can be adjusted, the sub-health state can be improved, the body is younger, the skin is younger, and the effect of prolonging the life is achieved.

The invention provides metoprolol slow-release microsphere, slow-release medical composition and a preparation method of the metoprolol slow-release microsphere. The metoprolol slow-release microsphere comprises 8-40wt% of active pharmaceutical ingredients and 60-92wt% of slow-release materials, wherein the active pharmaceutical ingredients contain metoprolol succinate, metoprolol tartrate or metoprolol hydrochloride, and the slow-release materials include 65-75wt% of ethyl cellulose and 25-35wt% of poly amino methacrylate. The active pharmaceutical ingredients and the slow-release materials are dissolved in an organic solvent to prepare microsphere, then the microsphere and an excipient are mixed to be pressed into tablets or manufactured into capsules to achieve the slow-release medicalcomposition containing the metoprolol slow-release microsphere. The medical composition is simple in prescription, low in toxicity, high in package rate, strong in controllability, good in reproducibility and low in cost.

The invention provides a metoprolol tartrate sustained-release tablet and a preparation method thereof. The tablet is composed of the components of, by weight: 30-50% of metoprolol tartrate, 15-30% of a sustained-release framework material, 0.35-10.0% of a lubricant, 10.0-30.0% of an adhesive, 0.5-5.0% of a film coating premix, and 10.0-30.0% of purified water. Compared with prior art, the tablet and the method provided by the invention have the advantages of simple preparation method, low production cost, suitability for industrialized productions, no greasy and sticky phenomenon during a production process, and smooth release curve. With the tablet, a sudden release phenomenon of a first time period is prevented, and a phenomenon of unqualified release speed at a first time period is also prevented.

The invention provides a novel metoprolol tartrate-containing matrix sustained-release tablet, i.e. a metoprolol tartrate matrix sustained-release tablet with a regulation layer. The novel double-layer matrix sustained-release tablet with the regulation layer is prepared by adding the regulation layer on the basis of the traditional metoprolol tartrate matrix sustained-release tablet, can release medicines uniformly in 24 hours, overcomes the defects of the metoprolol tartrate sustained-release tablet in the prior art, and has the advantages of ideal release effect, simple process and low cost.

The present invention relates to a kind of metoprolol tartrate time-selected drug release pellet and preparation method thereof, the preparation is a multi-layer coated pellet preparation, the basic structure from inside to outside is respectively a blank pellet core, a drug layer, a swelling layer, Lag layer. Wherein, the drug layer contains metoprolol tartrate, adhesive and anti-sticking agent. The swelling layer consists of a disintegrant and a binder. A non-water-soluble pore-forming agent and a water-soluble pore-forming agent are added to an ethylcellulose organic solvent as a lagging layer coating liquid. Time-selective drug release pellets were prepared by fluidized bed coating technology. The metoprolol tartrate timed-release pills provided by the invention have obvious timed-release characteristics, can guarantee a 4-hour time lag and a faster drug release rate after the time lag, and the drug release amount is greater than 2 hours after the immediate lag. 90%. The auxiliary materials used in the invention are easy to obtain and low in cost, the production process is simple and easy to operate, and the curing time for film formation of the lag layer is saved, which is suitable for industrial production.

The invention belongs to the field of medicinal preparation and discloses a metoprolol tartrate sustained release pellet and a preparation method thereof. The pellet is prepared by the following steps: preparing a parent kernel and a pellet core by using a centrifugal granulation method and spraying a sustained release coat on the pellet by using a fluidized bed coating method; and the method specifically comprises the following steps: (a) preparation of the parent kernel: taking metoprolol tartrate fine powder; adding the metoprolol tartrate fine powder into a pellet processing machine; spraying a wetting agent into the fine powder so as to form a certain number of parent kernels; and screening the parent kernels by using a screening method; (b) preparation of the pellet core: taking the parent kernels; adding the parent kernels into the pellet processing machine; spraying a wetting agent so that the surfaces of the parent kernels are wet; meanwhile, feeding the metoprolol tartrate fine powder into the pellet processing machine so that the parent kernels are laminated to be grown to pellet cores; and screening the pellet cores by using a screening method so as to obtain target pellet cores; and (c) coating of the pellet cores: taking the pellet cores; adding the pellet cores into a fluidized bed; and spraying sustained release coats on the pellet cores by using the fluidized bed coating method. The metoprolol tartrate sustained release pellet disclosed by the invention has the advantages of high true sphericity, small particle size, uniform particle size distribution, low production cost and medicine content of 100% in the pellet core.

The invention provides a preparation method of a metoprolol tartrate sustained release preparation. The preparation method is characterized in that the metoprolol tartrate is dissolved in 95% ethanolto obtain a solution A, and hydroxypropyl beta-cyclodextrin and mannitol are added in the solution A to obtain a solution B; polylactic acid and polyethylene glycol 200 are dissolved in acetone to obtain a solution C, the solution B and the solution C are mixed to obtain a solution D, the solution D is transferred to a magnetic stirrer, the solution D is continuously stirred for 12 hours, the temperature of the solution D is lowered to 0 DEG C to 1 DEG C in 2 hours and the solution D is subjected to standing for 12 hours, and the temperature of the solution D is kept to 0 DEG C to 1 DEG C during a standing period; after standing for 12 hours, the solution D is heated, when the temperature of the solution D is increased to 15 DEG C to 18 DEG C, the solution D is continuously stirred, when the temperature of the solution D is controlled at 15 DEG C to 18 DEG C while stirring, after the material is continuously stirred for 12 hours, the metoprolol tartrate sustained release preparation isprepared by a low-temperature spray-drying method. The dosage of a capsule material is moderate, the drying temperature of the material is low, the obtained drug-loading preparation is uniform, the drug release is stable, and the metoprolol tartrate sustained release preparation has sustained release characteristics.